Juno Bio, a women’s health company dedicated to closing the gender health gap through precision vaginal microbiome testing and multi-omics, announced the opening of its first sequencing lab built entirely for women’s health. The new facility, located in Oakland, California, marks a step forward in expanding access to high-quality, clinically relevant microbiome testing. To fuel this stage of growth, the company has raised $3.8 million in funding from investors including Ada Ventures, Artesian, Entrepreneur First, and Illumina Accelerator.
Since its founding, Juno Bio has built one of the largest repositories of vaginal microbiome data, helping thousands of women access more precise testing and treatment after launching its first wellness test, which has sold more than 20,000 units organically. The company has since evolved into a clinical platform, expanding its scientific and clinical infrastructure through pharmaceutical R&D partnerships, its own clinical lab, telehealth and pharmacy integrations, and a growing network of medical advisors.
The company’s new clinically actionable vaginal microbiome and STI test is processed in its own CLIA-certified lab and analyzes approximately 10,000 bacteria and fungi, along with four common STIs, to give patients and clinicians a detailed picture of the vaginal ecosystem. Unlike traditional tests that focus on a limited set of pathogens, the platform can help identify microbes associated with co-infections, subclinical conditions, and broader microbiome patterns, supporting more informed next steps across care, lifestyle, sexual health practices, and prescribed medication. According to the company’s data, prior to using its test, 67.5% of customers had been incorrectly diagnosed, whether misdiagnosed, underdiagnosed, or overdiagnosed, and only 13% had been successfully treated, while roughly half of users experience co-infections that are often missed by conventional testing. The test is currently available in 46 states, with additional expansion planned.
KEY QUOTES:
“Vaginal microbiome testing has the potential to significantly reshape how we understand and manage vaginal health, particularly for patients with recurrent or unexplained symptoms. While the field is still evolving, advances in sequencing and data interpretation are moving us closer to a future where more personalized, microbiome-informed care can complement existing diagnostic approaches.”
Anna Powell, MD, Johns Hopkins
“Over the past five years, Juno Bio has grown from a pioneering vaginal microbiome test into a clinical platform advancing a new standard of care for women’s health. We’ve built one of the largest repositories of vaginal microbiome data, helped thousands of women access clearer answers, expanded our clinical and scientific infrastructure, and deepened our partnerships across research and care delivery. This next chapter is about scaling that work, expanding access to more actionable care, and continuing to close the gender health gap.”
Hana Janebdar, Founder and CEO of Juno Bio
“Juno Bio is setting a new standard for how vaginal health is understood and managed. What they’ve built at this stage, with this level of capital efficiency, is exceptional. We’re proud to support the team as they scale their clinical infrastructure and continue leading innovation in this critically underserved category.”
Check Warner, Co-founding Partner at Ada Ventures
“The vaginal microbiome is still one of the least understood systems in the body at a clinical scale. With our lab, we’re starting to build a measurement standard that clinicians can actually use. We believe the level of detail from this kind of testing can meaningfully improve how vaginal healthcare is provided.”
Leighton Turner, PhD, Founder and CSO of Juno Bio
